CEA and AFP expression in human hepatoma cells transfected with antisense IGF-I gene *

ZHANG Li¹, LI Shu-Nong² and WANG Xiao-Ning¹

Abstract

AIM To determine whether antisense insulin-like growth factor-I (IGF-I) gene can modulate CEA and AFP expression in human hepatoma cells (HepG2).

METHODS Transfection of HepG2 cells was accomplished using Lipofectin reagent. Northern blot analysis confirmed the antisense IGF-I RNA of the transfected cells. CEA and AFP levels were measured using radioimmunoassay.

RESULTS Human hepatoma cell lines (HepG2) were transfected with antisense IGF-I gene. Northern blot analysis confirmed that antisense IGF-I RNA was expressed in the transfected cells. The effect of antisense IGF-I gene on CEA and AFP expression was demonstrated by the fact that the CEA and AFP levels in the supernatant of transfected cell culture were significantly lower as compared with the parent cells, [CEA 7.0 µg/L ± 0.76 µg/L and 3.29µg/L ± 1.80 µg/L (P < 0.05) and AFP 53.63 µg/L ± 6.02 µg/L and 9.0 µg/L ± 5.26 µg/L (P < 0.01), respectively].

CONCLUSION The malignant potentiality of the transfected cells was partially suppressed. Antisense IGF-I gene can modulate the expression of CEA and AFP in human hepatoma cell lines (HepG2)

MATERIAL AND METHODS

Cell lines and materials

Human hepatoma cells were purchased from the Institute of Shanghai Cell Biology. Antisense IGF-I expression plasmid was obtained from the University of Case Western Researve. Hygromycin was purchased from Sigma. Lipofectin and RPMI-1640 were purchased from GIBCO. The DIG system for hybridization was purchased from Boehringer Mannheim Biochemica. The CEA and AFP kit were the products of Institute of Shanghai Biologic Products.

The antisense IGF-I plasmid preparation and its DNA separation, appraisal and purification

Detailed methodology followed Klieig Ler M[5] and Trojan et al[3]'s.
Antisense IGF-I gene transfer into tumor cells mediated by Lipofectin

Transfection of HepG2 cells was accomplished using Lipofectin reagent (GIBCO) according to the instructions. Solution A: 100 µl RPMI-1640 containing 10 µg/L antisense IGF-I gene. Solution B: 90 µl RPMI-1640 containing 10 µl Lipofectin. Both solutions were mixed gently, and placed at room temperature for 15 min. Two serum-free RPMI-1640 was added to each tube containing the Lipofectin reagent-DNA complexes, and mixed gently and overlay out cells. The cells were incubated for 5h - 12h at 37°C in a CO2 incubator. Two ml of RPMI-1640 was supplemented with 10% FCS and the cells were incubated at 37°C, 5% CO2 incubator for another 48h. The cells grow in the presence of hygromycin until positive clones were selected.

Northern blotting hybridization
Total RNA in cells was extracted according to Kliegl Ler M[6]. Transfer blot hybridization was carried out as described in manual of DIG system kit. A dilution series of the total RNA was transferred to Nylon membrane and baked for 30min at 120°C. The membranes were put in a sealed plastic bag and used for Northern hybridization

Measurement of CEA
CEA kit contained CEA marker, 125I-CEA, CEA antibody and immune separation reagent. The operation and analysis of the results were carried out according to the manual.

Measurement of AFP
AFP kit contained marker, 125I-AFP, first antibody of AFP, analysis reagent of AFP and second antibody of AFP. The operation and analysis of the results were carried out according to the manual.

Statistical methods
Data were analyzed using the Student’s t test.

RESULTS
The analysis of Northern Blot
The antisense IGF-I plasmid was purified by abstraction and electrophoresis. It was wrapped up by Lipofectin and conducted into human hepatoma cells (HepG2). IGF-I antisense transcripts were selected in the presence of hygromycin. The total RNA in positive clone was extracted and its RNA transcription levels were analyzed by Northern Blot hybridization (Figure 1). The results showed that strong expression of the antisense transcript and the IGF-I transcripts of parent HepG2 cells was not apparent.

Figure 1 Northern blot analysis of antisense IGF-I transcripts in human HepG2 cells. Lane A, RNA of transfectants cells, Lane B, RNA of parents cells.

Figure 2 Expression of CEA in human HepG2 cells transfected with antisense IGF-I gene and parents HepG2 cells.

Figure 3 Expression of AFP in human HepG2 cells transfected with antisense IGF-I gene partents HepG2 cells.
**CEA levels of HepG2 cells transfected with antisense IGF-I**

The transfectant cells were kept in the presence of hygromycin for 8-12 days. After the transfectants and parent cells were cultured for 24 hours, the supernatants were collected and CEA levels were determined (Figure 2). The CEA levels of positive clones were markedly lower than that of the parent cells (7.0 µg/L ± 0.76 µg/L and 3.29 µg/L ± 1.80 µg/L, respectively) (P<0.05).

**The levels of AFP of antisense IGF-I transfectants of HepG2**

The supernatants were collected by the same method for CEA. AFP levels are shown in Figure 3. The AFP levels of positive clones were lowered markedly as compared with parent cells (53.63 µg/L ± 6.02 µg/L and 9.0 µg/L ± 5.26 µg/L, respectively) (P<0.01).

**DISCUSSION**

It has been known for a long time, abnormal materials related with the diseases existin the sera of cancer patients. The tumor markers are used for the diagnosis, prognosis and treatment of tumor. Although, the tumor markers were expressed nonspecifically by tumors and produced differently, there are still important indexes to predict carcinogenesis. CEA and AFP are carcinoembryonic protein. They appear in the embryonic term and disappear in adult. When they appear in the serum of adult, it shows that the growth of tumor was active so that these proteins were secreted into the blood. The half-life of CEA and AFP in plasma were 6-8 and 6.5 days. Recent reports indicated that CEA was a member of immunoglobulin supergene family[6]. Both were important tumor markers in the course of the carcinogenesis and development. As both were regarded as the index of the tumor biological changes and of the malignant degree in vivo, in this study, CEA and AFP were used as the index of positive clone biological changes after tumor was transfected by antisense IGF-I gene. It showed that antisense IGF-I gene affect the changes of tumor markers related with malignancy of the tumors. Because many gastrointestinal tumors were produced by CEA and AFP, human hepatoma cells (HepG2) were selected as the target tumors. Antisense IGF-I gene was wrapped up and transfected into the HepG2 cells, and cells grew in the presence of hygromycin for the positive clone. Northern Blots proved that transfectants of HepG2 cells showed detectable antisense IGF-I transcripts. The positive clone grew in the presence of hygromycin for 8-12 days. After the transfectants and parent cells were adjusted to 2×10^6/well for 24 hours the supernatants were collected. Figures 1-2 show the results of radioactive immune technique. The CEA and AFP levels of positive clones were markedly lower than that of the parent cells (CEA, 7.0 µg/L ± 0.76 µg/L and 3.29 µg/L ± 1.80 µg/L (P<0.05) and AFP, 53.63 µg/L ± 6.02 µg/L and 9.0 µg/L ± 5.26 µg/L (P<0.01), respectively. The results indicated that transfectants could affect the levels of CEA and AFP. When the secretive levels of both decreased, it suggested that malignancy of positive clone was lower than that of the parent cells and original biological courses were changed. At present, a lot of papers show that many kinds of tumors expressed abnormal IGF-I and suggest the involvement of the continuous proliferation and tumorigenic phenotype[2]. After antisense IGF-I gene was transfected into target cells, a specially nucleotide sequence was expressed in cells that was complementary to a portion of IGF-I gene in target cells. The process and transcript of IGF-I mRNA were inhibited. As the secretion of IGF-I in target cells were changed, it could affect the role of biology in cells, the event could inhibit the growth and the tumorigenicity of rat glioblastoma cells and murine teratocarcinoma in vivo[3,4]. That antisense IGF-I gene blocks the corresponding IGF sequences may be the reason for the decrease of CEA and AFP in target cells. The exact machanisms await further researches.

**REFERENCES**

1. Froesch ER, Schmid Chr, Schwander J, Zapf J. Actions of insulin-like growth factors. Annu Rev Physiol, 1985;47:443 - 467
2. Macaulay VM. Insulin-like growth factors and cancer. Br J Cancer, 1992;65 (3):311-320
3. Trojan J, Johnson TR, Rudin SD, Ilan J, Tykocinski ML, Ilan J. Treatment and prevention of rat glioblastoma by C6 cells expressing antisense IGF-IRNA. Science, 1993;259(5091):94 - 97
4. Trojan J, Johnson TR, Rudin SD, Bloosrey BK, Kelley KM, Shevelev A et al. Gene therapy of murine teratocarcinoma: separate functions for insulin-like growth factors I and II in immunogenicity and differentiation. PNAS, 1994;91(13): 6088 - 6092
5. Kriegler M. Gene transfer and expression. New York: M Stockton Press, 1990:47 - 81
6. Zimmerman W. Recent development concerning the carcinoembryonic gene family and their clinical implications. Tumor Biol, 1990;11(1-2):1 - 4